EI
TXMD icon

EAM Investors’s TherapeuticsMD TXMD Stock Holding History

EAM Investors’s Portfolio TXMD Stock Details TXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-10,056
Closed -$4.27M – 365
2016
Q2 		$4.27M Sell
10,056
-114
-1% -$47K 0.64% 10
2016
Q1 		$3.25M Buy
10,170
+1,283
+14% +$438K 0.51% 46
2015
Q4 		$4.61M Buy
8,887
+6,382
+255% +$2.36M 0.6% 22
2015
Q3 		$734K Sell
2,505
-547
-18% -$194K 0.12% 283
2015
Q2 		$1.2M Buy
+3,052
New +$1.08M 0.14% 276
2014
Q2 		– Sell
-6,843
Closed -$2.16M – 365
2014
Q1 		$2.16M Buy
6,843
+2,405
+54% +$766K 0.39% 74
2013
Q4 		$1.16M Buy
+4,438
New +$972K 0.21% 271

Other funds holding TXMD

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

EAM Investors's TXMD Position: Q3 2016 in Review

EAM Investors sold out of TherapeuticsMD (TXMD) in Q3 2016, closing a stake of 10,056 shares — an estimated $4.27M sold.

EAM Investors first reported a position in TXMD in Q4 2013 and held it in 7 quarters. The position peaked at $4.61M in Q4 2015. 137 funds tracked by Wall St. Rank hold TXMD as of Q3 2016.

  • EAM Investors reported no remaining TherapeuticsMD position as of Q3 2016 after selling out during the quarter.
  • EAM Investors sold 10,056 TherapeuticsMD shares in Q3 2016, an estimated $4.27M.
  • EAM Investors first reported a position in TherapeuticsMD in Q4 2013 and held it in 7 quarters.
  • EAM Investors's TherapeuticsMD position peaked at $4.61M in Q4 2015.
  • 137 funds tracked by Wall St. Rank held TherapeuticsMD as of Q3 2016.

Based on EAM Investors's 13F filing for Q3 2016, filed 10 Nov 2016.